Anavex Life Sciences Corp (AVXL)

[attilathehunt]

The more I study the issue (MS omitted on page 4 "pipeline overview" and included MS/WSU?Biogen on page 36 "targeted indications"), does make one wonder that it is omitted from OUR pipeline because a deal has been agreed to in principle where Biogen assumes the pipeline role with MS....and it is included on the target indication page because OUR drug A2-73 is continuing to be targeted for MS (It's just that we are not doing it). I think this is the most logical reasoning discussed thus far.

What other logical explanations are there? Omitting MS on page 4 and including on page 36 (as sloppy) is not logical to me. Too much time preparing and reviewing, so I can't see the type of mistake happening.

The plot thickens!